Author:
Ferguson William,Babic Aleksandar
Publisher
Springer International Publishing
Reference86 articles.
1. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps); August, 2007. https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/UCM091345.pdf.
2. Foundation for the Accreditation of Cellular Therapy (FACT). International standards for hematopoietic cellular therapy product collection, processing, and administration. 6th ed; March, 2015.
3. Prasad VK, Kurtzberg J. Cord blood and bone marrow transplantation in inherited metabolic diseases: scientific basis, current status and future directions. Br J Haematol. 2010;148(3):356–72.
4. Kekre N, Tokessy M, Mallick R, McDiarmid S, Huebsch L, Bredeson C, Allan D, Tay J, Tinmouth A, Sheppard D. Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction? Biol Blood Marrow Transplant. 2013;19(12):1719–24.
5. Anasetti C. Use of alternative donors for allogeneic stem cell transplantation. Hematology Am Soc Hematol Educ Program. 2015;2015(1):220–4. PubMed PMID: 26637725 . Epub 2015/12/08.eng.